AB0118 DIAGNOSTIC PREDICTIVE VALUE OF SOLUBLE PSGL-1 AND THEIR LIGANDS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Background Rheumatic diseases are generally diagnosed in advanced stages. Systemic lupus erythematosus (SLE) systemic inflammatory autoimmune disease characterized by presence of autoantibodies against DNA and nuclear proteins a wide variety clinical symptoms (Fava 2019, Wang 2019 ). Actually, it has not curative treatment (Mathias 2020 Therefore, the search for biomarkers SLE diagnosis earlier stages its derived complications is mandatory (Thanou 2021, Wan 2018 Adhesion molecules crucial to leukocytes infiltration inflammation sites (Ponthieux 2004, Ivetic Tinoco 2017 ), thus they play an important role have been suggested as useful markers prognosis rheumatic (Gonzalez-Tajuelo 2017, Skeoch 2014, da Rosa Franchi Objectives To study possible involvement adhesion development disease, we analysed pattern PSGL-1 serum levels together with main ligands P- E- L-selectins ADAM8 patients. Methods Serum samples from 52 patients, 36 inactive (iSLE) 16 active (aSLE) 55 healthy donors (HD) sex age matched per group were collected measured available ELISA kits: Human PSGL-1/CD162 kit (Novus Biologicals, Colorado, USA), Selectins/CD62 kits CD62E, CD62L CD62P (Diaclone, France), (A Disintegrin And Metalloprotease 8) Kit (Elabscience, Texas, USA). Results patients showed statistically significant increase PSGL-1, E-Selectin decrease L-Selectin respect HD. No difference observed between Patients anti-dsDNA and/or anti-SSA lower level higher compared absence these autoantibodies. Importantly, expression profile revealed that L-Selectin/ADAM8 ratio good predicted marker multivariable binary logistic regression model (OR=1,701, CI:1,188-2,450, p<0.005). Receiver operating characteristic (ROC) curve presented area under (AUC) 0.80 optimal cut off value maximizing sensitivity (98%) specificity (48%) jointly corresponded ratio<2,06. In this 97% correctly grouped. Conclusion show significantly different E-Selectin, controls. This specific protein could be potentially valuable tool early SLE. References [1] Fava A et all. Journal Autoimmunity Jan; 96:1-13. [2] González-Tajuelo R Frontiers Immunology Nov 12;11:588212 [3] (10): Article 1068 (pag 1-22) [4] Mathias LM Expert Opinnion Therapy Targets Dec; 24 (12): 1283-1302 [5] Ponthieux Atherosclerosis 2004 172: 299–308 [6] Franchi-Santos LF Lupus Mar; 27(3):380-388. [7] S 2014 Jul; 23(8):819-24 [8] Thanou 2021 May; 119:102615. [9] Trends 38(5): 323–335. [10] L J Clinical Laboratory Analysis 32(4):e22361 [11] X Jul 17; 10:1667. Acknowledgements work was supported Spanish Ministry Health ISCIII (co-financed Fondos FEDER) (FIS-PI17-01819, FIS-PI20-01690 project “Molecular stratification giant cell arteritis tailor glucocorticoid tocilizumab therapy (START Project)”, funded FOREUM, Foundation Research Rheumatology. Disclosure Interests None Declared.